Oral oncology最新文献

{"title":"Commentary on “Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma”","authors":"Gnanaprakash Jeyaraj","doi":"10.1016/j.oraloncology.2025.107741","DOIUrl":"10.1016/j.oraloncology.2025.107741","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107741"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145275453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer","authors":"Rose Doerfler ,&nbsp;Jie Chen ,&nbsp;Carl Kim ,&nbsp;Joshua D. Smith ,&nbsp;Micah Harris ,&nbsp;Krishna B. Singh ,&nbsp;Brian Isett ,&nbsp;Rebekah E. Dadey ,&nbsp;Daniel D. Brown ,&nbsp;Adrian V. Lee ,&nbsp;Xuefeng Wang ,&nbsp;Matthew E. Spector ,&nbsp;Seungwon Kim ,&nbsp;Shaum Sridharan ,&nbsp;Kevin Contrera ,&nbsp;Katelyn Smith ,&nbsp;Carly Reeder ,&nbsp;Maureen Lyons ,&nbsp;Jianhua Luo ,&nbsp;Silvia Liu ,&nbsp;Riyue Bao","doi":"10.1016/j.oraloncology.2025.107742","DOIUrl":"10.1016/j.oraloncology.2025.107742","url":null,"abstract":"<div><div>Patient-derived organoids (PDOs) emerge as advanced 3D ex vivo New Approach Methodologies (NAM) preclinical models, offering significant advantages over traditional cell lines and monolayer cultures for therapeutic development. In this study, we established PDOs from surgically resected fresh tissues of human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC) across anatomical sites, tumor T-categories, and sample types. These PDOs faithfully recapitulate the tumor’s pathology, mutational profile, and drug response. To enable rapid classification of PDO identity, we developed a new convolutional neural network (CNN) model, TransferNet-PDO, which accurately distinguished tumor <em>versus</em> normal PDOs in culture using digital histopathology images (AUC ≥ 0.88). PDOs maintained stable cultures and were cryopreserved between passages 5 and 12. Immunohistochemistry (IHC) staining (PanCK, p63, Cytokeratin 13, Ki67) confirmed squamous phenotype and histologic aggression of the original tumor. For tumors harboring TP53 mutations by whole-exome sequencing (WES), PDOs retained the corresponding p53 functional status as confirmed by IHC (enhanced or loss of protein expression). Somatic mutational landscape revealed that PDOs preserved driver somatic mutations, copy number variations (CNVs), and clonal architecture including low-prevalence subclones. Drug sensitivity assessment of PDOs showed that cisplatin reduced cell viability, whereas cetuximab and lenvatinib had minimal effects. Chemoradiation led to greater tumor organoid killing compared to radiation or chemotherapy alone. This study presents an integrated HNSCC PDO platform combining tissue biobanking, organoid establishment, multiomics characterization, functional drug screening, and AI-driven histopathologic classification, providing a comprehensive and scalable system for translational cancer research.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107742"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145489953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer","authors":"Cecelia M. Hidalgo ,&nbsp;Gabriel A. Hernandez-Herrera ,&nbsp;Courtney N. Day ,&nbsp;Felicia Olawuni ,&nbsp;Chadi N. Abdel-Halim ,&nbsp;Kathryn M. Van Abel ,&nbsp;David M. Routman ,&nbsp;Linda X. Yin","doi":"10.1016/j.oraloncology.2025.107768","DOIUrl":"10.1016/j.oraloncology.2025.107768","url":null,"abstract":"<div><h3>Purpose</h3><div>De-escalation trials in human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV + OPSCC) have led to variable institutional treatment algorithms. It is unclear whether treatment options are offered equally throughout the United States. This study assesses how social determinants of health (SDOH), and treatment facility type impact access to surgery and/or high-quality radiotherapy (RT) for HPV + OPSCC.</div></div><div><h3>Results</h3><div>Among 6,458 patients, the median age was 62, 93.1 % were White, and 79.2 % had no significant comorbidities. Patients with the highest education, income, and private insurance (p ≤ 0.002 for all) underwent more surgery. Patients with lower education and income presented with more advanced disease (each p &lt; 0.001). Care at academic facilities was the strongest predictor of surgery for early-stage disease (aOR:6.17, 95 % CI:3.74–10.18, p &lt; 0.001) and was more likely to result in a margin-negative resection (p = 0.017). Delays in TTI were highest among Black patients, uninsured patients, patients with low socioeconomic status (SES), and patients receiving care at academic facilities (p ≤ 0.011 for all). Patients with significant comorbidities were more likely to experience delays in TTA (p = 0.018) and TTC (p = 0.036). There were no differences in delays in TTA or TTC based on treatment facility.</div></div><div><h3>Conclusions</h3><div>SDOH affect access to surgery for HPV + OPSCC, with patients of low SES presenting with more advanced disease. Among early-stage cases, access to surgery is significantly greater at academic facilities, which offer superior surgical outcomes. Treatment completion times are comparable between academic and community facilities, suggesting that poor surgical candidates should pursue care at the facility offering the fastest treatment initiation and completion.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107768"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145496177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study","authors":"Paulien Van Loocke ,&nbsp;Benoit Beuselinck ,&nbsp;Jeroen Meulemans ,&nbsp;Sandra Nuyts ,&nbsp;Robin Willaert ,&nbsp;Davide Di Santo ,&nbsp;Esther Hauben ,&nbsp;Robert Hermans ,&nbsp;Abhishek D. Garg ,&nbsp;Vincent Vander Poorten ,&nbsp;Oliver Bechter ,&nbsp;Paul M. Clement","doi":"10.1016/j.oraloncology.2025.107772","DOIUrl":"10.1016/j.oraloncology.2025.107772","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107772"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145468318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Durable complete response to tislelizumab plus cetuximab in a 94-year-old patient with advanced lower lip squamous cell carcinoma: A case report and literature review","authors":"Shi-Qiong Zhou ,&nbsp;Sen Zhang ,&nbsp;Qing-Hua Ke","doi":"10.1016/j.oraloncology.2025.107765","DOIUrl":"10.1016/j.oraloncology.2025.107765","url":null,"abstract":"<div><h3>Background</h3><div>Lip squamous cell carcinoma (SCC) is a rare subtype of head and neck squamous cell carcinoma (HNSCC), accounting for approximately 1 % of all oral malignancies. Unlike other oral SCCs (e.g., tongue or buccal SCC), lip SCC has distinct epidemiological features: it shows a stronger association with chronic sun exposure (especially ultraviolet radiation) and a lower correlation with smoking/alcohol consumption. It is more common in elderly males, and advanced cases with lymph node metastasis are associated with poor prognosis. The treatment of advanced lip SCC in elderly patients is uniquely challenging due to its anatomical location (functional and aesthetic importance), which makes aggressive therapies like surgery more likely to cause functional impairment (e.g., difficulty in mouth opening or speech) and poor tolerance to such therapies due to comorbidities [1–3].</div></div><div><h3>Case summary</h3><div>A 94-year-old female patient presented with a progressively enlarging mass on the right lower lip, which was diagnosed as poorly differentiated squamous cell carcinoma with neck lymph node metastasis (cT4N2M0). Due to her advanced age and late-stage disease, she was not eligible for surgery, radiotherapy, or chemotherapy. She received combination therapy with tislelizumab (200 mg intravenously every 3 weeks) and cetuximab (400 mg/m² intravenously every 2 weeks) starting from November 27, 2024. Significant improvement of the lip mass was observed after treatment, and complete response was achieved on January 8, 2025, after two cycles of treatment. Consolidation therapy was continued for six months, with no recurrence or metastasis during follow-up. As of July 31, 2025 (6 months after initial treatment), the patient remains in complete response with regular follow-up. Immunohistochemical analysis showed PD-L1 positivity with a combined positive score (CPS) of 80, which may predict a favorable response to immunotherapy.</div></div><div><h3>Conclusion</h3><div>This case demonstrates that the combination of tislelizumab and cetuximab can achieve remarkable efficacy in elderly patients with advanced lip SCC, even without surgery, radiotherapy, or chemotherapy. PD-L1 high expression (CPS = 80) may serve as a valuable predictive biomarker for immunotherapy response in such cases. Six months follow-up confirms the durability of the response, supporting the potential of this regimen in extreme elderly populations.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"171 ","pages":"Article 107765"},"PeriodicalIF":3.9,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145420250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Whole-exome sequencing reveals the mutational landscape of head and neck lymphoepithelioma-like carcinoma","authors":"Thangapandi Marudhupandi","doi":"10.1016/j.oraloncology.2025.107740","DOIUrl":"10.1016/j.oraloncology.2025.107740","url":null,"abstract":"<div><div>The recent article by Zhang et al. titled “Whole-exome sequencing reveals the mutational landscape of head and neck lymphoepithelioma-like carcinoma” makes a significant contribution to understanding this rare cancer. Using whole-exome sequencing, the authors identified frequently mutated genes, potential driver mutations, and candidate treatments, offering valuable insights into the molecular basis of HNLEC. Importantly, they identified links between specific gene alterations and patient outcomes, as well as druggable pathways, through DGIdb analysis. Although limited by sample size, this pioneering study provides a genomic foundation that can guide future research. Larger multi-institutional studies, functional testing of candidate driver genes, and the incorporation of viral and immune profiling will be the next steps in turning these findings into clinical applications. This work provides a strong base for advancing precision oncology in HNLEC.</div></div>","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107740"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145233103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: The role of adjuvant radiotherapy in relation to tumor size for bone-invasive pT4aN0 oral squamous cell carcinoma – A retrospective observational matched cohort study","authors":"Shenghao Lin ,&nbsp;Leyin Zhang ,&nbsp;Leitao Sun","doi":"10.1016/j.oraloncology.2025.107732","DOIUrl":"10.1016/j.oraloncology.2025.107732","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107732"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: the lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma","authors":"Yanan Duan","doi":"10.1016/j.oraloncology.2025.107702","DOIUrl":"10.1016/j.oraloncology.2025.107702","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107702"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145258771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!","authors":"Satya Ranjan Misra,&nbsp;Rupsa Das","doi":"10.1016/j.oraloncology.2025.107718","DOIUrl":"10.1016/j.oraloncology.2025.107718","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107718"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145120090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma","authors":"Min Li,&nbsp;Yingchun Zhou,&nbsp;Ming Cai","doi":"10.1016/j.oraloncology.2025.107725","DOIUrl":"10.1016/j.oraloncology.2025.107725","url":null,"abstract":"","PeriodicalId":19716,"journal":{"name":"Oral oncology","volume":"170 ","pages":"Article 107725"},"PeriodicalIF":3.9,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145120092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}